Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first...

Point of Care Decision Support Releases New Version of Anticoagulation Software

Image courtesy of Point of Care Decision Support

Technology | Clinical Decision Support | April 30, 2018

April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their...

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American...

Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018

March 22, 2018 — The experimental ...

Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018

March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart...

Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the...

Reducing Co-Payments Improves Patient and Physician Adherence to Guideline-Recommended Treatment Post-Heart Attack, late-breaking trial at ACC.18.

Image from presentation, "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study," Wang 

News | ACC | March 20, 2018

March 20, 2018 — When patients who had a heart attack were given vouchers to cover their co-payments for...

Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

Image from presentation, "The PHARMCLO Study," Diego Ardissino, M.D., F.A.C.C. 

News | ACC | March 20, 2018

March 20, 2018 — Patients with acute coronary syndrome experienced a substantially lower rate of heart attack,...

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018

March 19, 2018 — The combined rate of death from any cause, heart attack or stroke within 18 months was not...

Aspirin Lowers Risk of Death for Patients with Diabetes, Heart Failure
News | ACC | March 15, 2018

March 15, 2018 — For people living with both Type 2 diabetes and heart failure, taking an...

The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of...

Alirocumab Reduces Cardiovascular Events after Acute Coronary Syndrome
News | ACC | March 13, 2018

March 13, 2018 –  Among patients with persistently high cholesterol despite high-intensity statin therapy, the...

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

February 13, 2018 — Abbott announced the first patient has been enrolled in a...

Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018

January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of...

Overlay Init